New drug could help rare fat disorder patients
NCT ID NCT07220785
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 4 times
Summary
This study tests a new drug called mibavademab for people with generalized lipodystrophy, a rare condition where the body lacks fat tissue. The goal is to see if the drug can improve blood sugar, lower blood fats, and reduce liver fat. About 28 children and adults will take part in this phase 3 trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assistance Publique-Hopitaux de Paris (AP-HP)
RECRUITINGParis, 75571, France
-
Hopital Universitaire Robert-Debre
RECRUITINGParis, 75019, France
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for youngest kids with rare fat disorder
- Rare fat disorder drug under microscope: new safety data emerges
- New drug shows promise for rare fat disorder
- Lifesaving drug made available for rare fat disorder patients
- New hope for rare fat disorder: experimental drug mibavademab under safety review